Wision AI, a leader in developing computer-aided diagnostic algorithms and real-time systems to improve the accuracy and effectiveness of diagnostic imaging, today announced the publication of data demonstrating positive results and competitive advantages of using its artificial intelligence computer-aided polyp detection (CADe) system during colorectal cancer screening in a U.S. patient population. In this world’s first external independent randomized controlled trial (RCT) of AI in the medical field conducted in the United States (NCT03925337), 232 patients were enrolled for screening and surveillance colonoscopy in four leading U.S. academic institutions. Results indicated that the Wision AI‘s CADe device, EndoScreener, significantly reduced the adenoma miss rate (31.25% vs. 20.12%, p=0.0247) and increased adenoma detected per colonoscopy (0.90 vs. 1.19, p=0.0323). The trial data have been published in Clinical Gastroenterology & Hepatology.i
“Our study demonstrates that computer-aided polyp detection has the potential to decrease variability in colonoscopy quality among providers by reducing the miss rate even for experienced physicians,” said senior study author Tyler M. Berzin, MD, director of the Advanced Endoscopy Fellowship at Beth Israel Deaconess Medical Center. “While traditional colonoscopy already detects precancerous polyps earlier and more effectively than stool DNA tests and “virtual” CT scan colonography, the addition of AI polyp detection tools will further support the role of colonoscopy as the gold standard for colorectal cancer screening and prevention.”